World Health Organization Issues Alert Over Acute Lack of Weight-Loss Jabs

Under one in 10 people that would benefit from GLP-1 drugs like Wegovy have access to them, states the WHO as it issues its first guidance on the therapies.

Given over a billion individuals worldwide now living with obesity, it is calling for more widespread and fairer availability to this class of drugs.

Per projections, more than two billion will be obese by 2030 unless action is taken.

"Our latest guidelines recognises that obesity is a chronic disease that can be treated with comprehensive and lifelong care," stated its chief Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and distribution challenges are major obstacles to universal availability to the treatments that can aid individuals in losing substantial weight, says the agency.

Weight-Loss Drug Supply Crisis

Despite the present most favorable scenario, the production of these medications could only cover approximately 100 million people – fewer than 10% of the global need, per the WHO.

The advice encourages countries and companies to expand access, via measures such as voluntary licensing.

The intellectual property rights on the active ingredient – the main component of a leading brand – is due to expire in a number of nations in 2026.

How Weight-Loss Jabs Function

These medications imitate a natural hormone to reduce digestion speed, reduce hunger and enhance feelings of fullness so people eat less.

Individuals commonly see weight reduction after several weeks of beginning the regular doses.

Studies indicates users may put most of the weight back on a year later of stopping the drug, because their normal hunger resume.

Being above a healthy weight increases your risk for contracting medical conditions, including diabetes, heart disease, brain attack, and specific malignancies.

Obesity affects people in all nations and was responsible for millions of deaths worldwide in 2024, as per the health agency.